SynthesisPloS one2021
Evidence-based interventions implemented in low-and middle-income countries for sickle cell disease management: A systematic review of randomized controlled trials.
Synthesis in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Antioxidant supplementation for sickle cell disease.The Cochrane database of systematic reviews · 2024Pooled it
- Coping Skills, Hospitalizations, and Hopefulness in Youths with Sickle Cell Disease Treated in a Regional Outpatient Comprehensive Pediatric Center.Children (Basel, Switzerland) · 2026Article
- Clinical and laboratory characteristics of adolescents and young adults with sickle cell disease at steady state in Uganda.PLOS global public health · 2026Article
- Growth measurements in Ugandan children with sickle cell anaemia from a hydroxyurea (hydroxycarbamide) treatment trial relative to unaffected sibling controls.British journal of haematology · 2025Article
- Strategies for reducing child mortality due to sickle cell disease in Uganda: a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Effect of empowerment-based interventions on self-efficacy and self-care capacity among patients with sickle cell disease: A randomized controlled trial.International journal of nursing sciences · 2025Article
- Burden of hemoglobinopathies and hemolytic anemias in the World Health Organization African region, 2000-2021: Findings from the Global Burden of Disease 2021 study.PLOS global public health · 2025Article
- Improving access to healthcare services for sickle cell disease patients in Nigeria: perspectives and views of healthcare professionals.Frontiers in health services · 2025Article
- Barriers and facilitators to implementing a task-sharing mental health intervention for Sickle Cell Disease populations in low- and middle-income countries: a qualitative analysis using the Consolidated Framework for Implementation Research (CFIR).Frontiers in public health · 2025Article
- Self-management needs, strategies and support for individuals with sickle cell disease in developing countries: a scoping review.BMJ open · 2024Article
- Self-management needs, strategies and support for sickle cell disease in developing countries: a scoping review protocol.BMJ open · 2024Article
- The value-based price of transformative gene therapy for sickle cell disease: a modeling analysis.Scientific reports · 2024Article
- Disparities in COVID-19 clinical studies from high-income and low-and middle-income countries.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Article
- Knowledge and nutrition-related practices among caregivers of adolescents with sickle cell disease in the Greater Accra region of Ghana.BMC public health · 2023Article
- A rapid evidence assessment of sickle cell disease educational interventions.Journal of clinical nursing · 2023Article
- Article
- The Consortium on Newborn Screening in Africa for sickle cell disease: study rationale and methodology.Blood advances · 2022Article
- Cost analysis of acute care resource utilization among individuals with sickle cell disease in a middle-income country.BMC health services research · 2022Article
- Barriers to Therapeutic Use of Hydroxyurea for Sickle Cell Disease in Nigeria: A Cross-Sectional Survey.Frontiers in genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite ~90% of sickle cell disease (SCD) occurring in low-and middle-income countries (LMICs), the vast majority of people are not receiving evidence-based interventions (EBIs) to reduce SCD-related adverse outcomes and mortality, and data on implementation research outcomes (IROs) and SCD is limited. This study aims to synthesize available data on EBIs for SCD and assess IROs.
methodsWe conducted a systematic review of RCTs reporting on EBIs for SCD management implemented in LMICs. We identified articles from PubMed/Medline, Global Health, PubMed Central, Embase, Web of Science medical subject heading (MeSH and Emtree) and keywords, published from inception through February 23, 2020, and conducted an updated search through December 24, 2020. We provide intervention characteristics for each study, EBI impact on SCD, and evidence of reporting on IROs. MAIN
results29 RCTs were analyzed. EBIs identified included disease modifying agents, supportive care agents/analgesics, anti-malarials, systemic treatments, patient/ provider education, and nutritional supplements. Studies using disease modifying agents, nutritional supplements, and anti-malarials reported improvements in pain crisis, hospitalization, children's growth and reduction in severity and prevalence of malaria. Two studies reported on the sustainability of supplementary arginine, citrulline, and daily chloroquine and hydroxyurea for SCD patients. Only 13 studies (44.8%) provided descriptions that captured at least three of the eight IROs. There was limited reporting of acceptability, feasibility, fidelity, cost and sustainability.
conclusionEBIs are effective for SCD management in LMICs; however, measurement of IROs is scarce. Future research should focus on penetration of EBIs to inform evidence-based practice and sustainability in the context of LMICs. CLINICAL
trial registrationThis review is registered in PROSPERO #CRD42020167289.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.